Literature DB >> 33982381

Wogonin alleviates liver injury in sepsis through Nrf2-mediated NF-κB signalling suppression.

Ji-Min Dai1,2, Wei-Nan Guo3, Yi-Zhou Tan4, Kun-Wei Niu1, Jia-Jia Zhang2, Cheng-Li Liu5,6, Xiang-Min Yang2, Kai-Shan Tao1, Zhi-Nan Chen2, Jing-Yao Dai5,6.   

Abstract

Sepsis is a life-threatening organ dysfunction syndrome, and liver is a susceptible target organ in sepsis, because the activation of inflammatory pathways contributes to septic liver injury. Oxidative stress has been documented to participate in septic liver injury, because it not only directly induces oxidative genotoxicity, but also exacerbates inflammatory pathways to potentiate damage of liver. Therefore, to ameliorate oxidative stress is promising for protecting liver in sepsis. Wogonin is the compound extracted from the medicinal plant Scutellaria baicalensis Geogi and was found to exert therapeutic effects in multiple inflammatory diseases via alleviation of oxidative stress. However, whether wogonin is able to mitigate septic liver injury remains unknown. Herein, we firstly proved that wogonin treatment could improve survival of mice with lipopolysaccharide (LPS)- or caecal ligation and puncture (CLP)-induced sepsis, together with restoration of reduced body temperature and respiratory rate, and suppression of several pro-inflammatory cytokines in circulation. Then, we found that wogonin effectively alleviated liver injury via potentiation of the anti-oxidative capacity. To be specific, wogonin activated Nrf2 thereby promoting expressions of anti-oxidative enzymes including NQO-1, GST, HO-1, SOD1 and SOD2 in hepatocytes. Moreover, wogonin-induced Nrf2 activation could suppress NF-κB-regulated up-regulation of pro-inflammatory cytokines. Ultimately, we provided in vivo evidence that wogonin activated Nrf2 signalling, potentiated anti-oxidative enzymes and inhibited NF-κB-regulated pro-inflammatory signalling. Taken together, this study demonstrates that wogonin can be the potential therapeutic agent for alleviating liver injury in sepsis by simultaneously ameliorating oxidative stress and inflammatory response through the activation of Nrf2.
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  Nrf2; liver injury; oxidative stress; sepsis; wogonin

Year:  2021        PMID: 33982381     DOI: 10.1111/jcmm.16604

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  5 in total

1.  Hepatoprotective Effect of Mitochondria-Targeted Antioxidant Mito-TEMPO against Lipopolysaccharide-Induced Liver Injury in Mouse.

Authors:  Peng-Fei Wang; Ke Xie; Yun-Xing Cao; An Zhang
Journal:  Mediators Inflamm       Date:  2022-06-20       Impact factor: 4.529

2.  Circular RNA VMA21 ameliorates lung injury in septic rat via targeting microRNA-497-5p/CD2-associated protein axis.

Authors:  JinFang Ke; MengFei Chen; ShiLan Ma; Liang Zhang; Ling Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  Adipose-derived stem cells alleviate liver injury induced by type 1 diabetes mellitus by inhibiting mitochondrial stress and attenuating inflammation.

Authors:  Yanli Hou; Wenyu Ding; Peishan Wu; Changqing Liu; Lina Ding; Junjun Liu; Xiaolei Wang
Journal:  Stem Cell Res Ther       Date:  2022-04-01       Impact factor: 6.832

Review 4.  The liver in sepsis: molecular mechanism of liver failure and their potential for clinical translation.

Authors:  Dustin Beyer; Jessica Hoff; Oliver Sommerfeld; Alexander Zipprich; Nikolaus Gaßler; Adrian T Press
Journal:  Mol Med       Date:  2022-07-30       Impact factor: 6.376

5.  Wogonin, a Compound in Scutellaria baicalensis, Activates ATF4-FGF21 Signaling in Mouse Hepatocyte AML12 Cells.

Authors:  Yasunari Yamada; Hodaka Saito; Masaya Araki; Yuhei Tsuchimoto; Shin-Ichi Muroi; Kyohei Suzuki; Kazufumi Toume; Jun-Dal Kim; Takashi Matsuzaka; Hirohito Sone; Hitoshi Shimano; Yoshimi Nakagawa
Journal:  Nutrients       Date:  2022-09-21       Impact factor: 6.706

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.